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Abstract
Background: A validated instrument to assess the effects of chronic cough on health status in patients with
chronic obstructive pulmonary disease (COPD) is currently not available. The Leicester Cough Questionnaire (LCQ)
is a cough-specific health status questionnaire which is originally validated for a population of general patients
presenting with chronic cough. We examined the psychometric performance of the LCQ in patients with COPD
and chronic productive cough.
Methods: Concurrent validity, internal consistency, reproducibility and responsiveness were determined. The St.
George’s Respiratory Questionnaire (SGRQ) and the Short Form-36 (SF-36) were used as external criteria.
Questionnaires were completed at the start of the study. After 2 and 12 weeks the LCQ was repeated, together
with a global rating of change.
Results: In total 54 patients were included. Concurrent validity analysis showed significant correlations between
corresponding domains of the LCQ and the SGRQ (rs -0.31 to -0.60). Corresponding domains of the LCQ and the
SF-36 showed weaker correlations (rs 0.04 to 0.41). Internal consistency was adequate for two of the three domains
(Cronbach’s a 0.74 - 0.86). Test-retest reliability in stable patients was high (intraclass correlation coefficients 0.79 -
0.93). The mean difference after two weeks was 0.73 (± 1.75). Responsiveness analysis indicated that the LCQ was
able to detect changes after 12 weeks.
Conclusion: The LCQ is a valid, reliable, responsive instrument to measure health status in COPD patients with
chronic productive cough.
Trial Registration: ClinicalTrials.gov: NCT01071161
Keywords: LCQ, COPD, validity, cough, health status
Background
COPD is a leading cause of morbidity and mortality all
over the world. In 2001 COPD was the fifth cause of
death and its relative importance is predicted to increase
in future years [1,2]. Detection of airflow limitation is
paramount in the GOLD definition of COPD [3,4], but
clinically COPD is characterized by chronic and pro-
gressive dyspnea, cough and sputum production [4,5].
Prevalence rates of chronic productive cough in the
male COPD population are estimated to be 15-44% and
6-17% in females. These rates increase with age and are
strongly related to smoking [6]. The high prevalence of
cough in COPD may be caused by increased production
of mucus, by the inability to produce a sufficiently large
expiratory flow leading to ineffective clearing of the
mucus, and by impaired mucociliary clearance leading
to mucus retention. Also, many patients with COPD
have bronchiectasis [7,8].
Chronic productive cough in COPD patients is asso-
ciated with severe exacerbations which require hospitali-
zation [9]. These exacerbations have serious effects on
health status and quality of life [10]. * Correspondence: f.f.berkhof@isala.nl
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agement goal in the GOLD guideline. To measure this,
assessment is recommended on regularly basis [4].
Although cough is a frequent symptom in COPD, the
impact of cough on health status in these patients is lar-
gely unknown [2]. One study found that only a small
part (2%) of the variance in the scores of the St.
George’s Respiratory Questionnaire (SGRQ), a disease-
specific health status questionnaire is explained by
cough [2]. Several cough-specific health status question-
naires have been developed and validated in the general
population presenting with cough but not necessarily
with COPD [11-15]. Of these questionnaires only the
Leicester Cough Questionnaire (LCQ) [16] is available
in Dutch [17]. Thus, well validated cough-specific health
status questionnaires for COPD patients are absent, ren-
dering it impossible to evaluate patients health status
both individually and in clinical trials.
In this paper we investigated the precision and validity
of the LCQ in COPD patients with chronic cough.
Methods
Study design
The study was designed as a prospective validation
study. Blinded data were used from a larger clinical trial
in which the effects of azithromycin on cough related
health status were studied. Patients were randomised
between azithromycin and placebo for twelve weeks and
started at day 1. The study was registered at Clinical-
Trials.gov (NCT01071161) and was approved by the
Ethics Committee of the Isala klinieken, Zwolle, Nether-
lands (NL19886.075.07, local number: 07.0971). All
questionnaires were administered during the first visit,
the LCQ was repeated after two and twelve weeks.
Subjects
Patients with COPD (GOLD II-IV) who were ≥ 40 years of
age were eligible to participate if they were suffering from
chronic productive cough, defined as productive cough for
at least three months a year, in two subsequent years. The
inclusion period lasted from September 2009 to Septem-
ber 2010. Exclusion criteria were: a prior history of
asthma, use of intravenous or oral corticosteroids and/or
antibiotics for an exacerbation three weeks before inclu-
sion, suffering from other relevant lung or liver diseases at
the discretion of the treating physician, pregnancy or lacta-
tion, use of macrolides in the last six weeks prior to inclu-
sion, allergy or intolerance to macrolides, or other study
medication started two months prior to inclusion.
Questionnaires
The LCQ is a cough-specific health status questionnaire
that is well validated in the general population. It con-
sists of 19 items which are divided over 3 domains:
physical, psychological and social. A 7-point Likert scale
is used to rate. It assesses the impact of cough over the
preceding 2 weeks. The total score ranges from 3-21; a
higher score corresponds to a better health status
[16,18,19]. We have previously described the validation
of the Dutch translation for the general population [17].
The St. George’s respiratory questionnaire (SGRQ) is a
disease-specific health status questionnaire for asthma
and COPD, which assesses the impact of symptoms
over the preceding 3 months. It contains 76 items
divided in 3 sections: symptoms, activity and impacts.
The scores range from 0-100, a low score indicates a
good health status [20,21].
The Short Form Health Survey (SF-36) questionnaire is
a self administrated generic health status questionnaire
containing 36 items that cover 9 health dimensions. The
SF-36 comprises 8 health scales: physical functioning,
role limitations physical, bodily pain, general health, vital-
ity, social functioning, role limitations emotional, and
mental health. One single item is used to assess any
change in health. Each dimension is scaled from 0-100,
higher scores represent better health status [22-26].
A global rating of change (GRC) was used to evaluate
self-perceived health change on a 15 point scale (-7 a very
great deal worse, 0 no change, +7 a very great deal better).
Validity & Precision
The following concepts were assessed to determine psy-
chometric performance of the LCQ in COPD: concur-
rent validity, internal consistency, reproducibility,
responsiveness and floor or ceiling effects.
Concurrent validity (appropriate correlations between
established measures and the new questionnaire) was
measured with the SGRQ and SF-36 [16]. Ideally, we
w o u l dh a v eu s e da na d d i t i o n a lc o u g h - s p e c i f i cq u e s t i o n -
naire. However, such questionnaires have not been spe-
cifically developed for, nor tested in COPD patients
[11-15]. We used the SGRQ as the reference standard.
Internal consistency concerns the degree to which
scores of items in a questionnaire correlate homoge-
neously, and was assessed using data from the LCQ of
the first visit.
Reproducibility is a measure of precision and concerns
the degree to which repeated measurements in a stable
persons (defined as GRC = -1, 0 and 1 in our study)
correspond. Reproducibility can be divided in agreement
and reliability [27]. Agreement concerns the closeness of
the results of repeated measurements after two weeks
and assessment is preferred if the aim is to measure
change in health status, whereas reliability denotes the
degree to which patients can be distinguished from each
other, despite measurement error [28]. Both parameters
were obtained by comparing the LCQ scores of week 0
and week 2.
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within-patient changes, even if they are small; it was
determined by comparing the LCQ scores of the first
visit with LCQ scores after 12 weeks in patients who
perceived a significantly improvement in cough symp-
toms (arbitrarily chosen as GRC≥4 (moderately better to
a very great deal better) in our study.
Furthermore the floor or ceiling effects can be
assessed if more than 15% of the patients achieve the
lowest or highest possible score, respectively. Absence of
floor or ceiling effects indicates a good content validity
[17,27].
Statistical Analyses
The concurrent validity was determined by calculating
correlation coefficients between LCQ-scores and scores
on SGRQ and SF-36. Depending on the distribution of
the variables Pearson correlation coefficients or Spear-
man rank correlation coefficients were used. We made a
priori assumptions of the associations between the LCQ
total and domain scores and the corresponding scores
of the SGRQ and SF-36, respectively. We expected cor-
relation coefficients ≥0.5 for associations between the
LCQ and SGRQ and ≥0.4 between the LCQ and SF-36.
Corresponding domains of the LCQ physical domain
were the SGRQ activity and symptoms domains, and for
the LCQ psychological and social domains the SGRQ
impact domain [20]. For the LCQ physical domain, the
corresponding domain of the SF-36 were the physical
functioning/role physical domains, and for the LCQ psy-
chological domain the SF-36 mental health domain and
for the LCQ social domain the SF-36 social functioning
domain [16].
Internal consistency of the LCQ was evaluated using
Cronbach’s alpha coefficients for the three domains and
the total LCQ. Cronbach’s alpha coefficients between
0.7 and 0.9 are considered as proof of internal consis-
tency. Agreement over time was assessed by construct-
ing a Bland-Altman plot for the LCQ total score [29].
Reliability was analysed by calculating Intraclass Corre-
lation Coefficients (ICC) for the 3 domains and the total
LCQ [17].
Responsiveness was measured as the area under the
receiver operating characteristic (ROC) curve which
indicates the probability of correctly identifying subjects
who report improvement [27,30].
Data analyses were performed using the Statistical
Package for the Social Sciences (SPSS) version 18.0
(SSPS, Chicago, IL, USA).
Results
Patients
Fifty-four patients met the inclusion criteria. All patients
were eligible in the cross-sectional analyses (concurrent
validity, internal consistency, floor or ceiling effects).
Data from 52 patients could be used for reproducibility
analysis. Data from 49 patients were used to test respon-
siveness. Two patients withdrew the informed consent
after one week. One patient stopped after 4 weeks
because of chronic diarrhoea. Two patients failed to
return the questionnaire after 12 weeks. Baseline charac-
teristics are shown in table 1 and 2. Most of the patients
were male and current smokers with moderate to severe
COPD.
Concurrent Validity
Since most of the distributions were skewed, Spearman
rank correlation coefficients were used. The correlation
coefficients are summarized in table 3. The concurrent
validity showed significant correlations between the cor-
responding domains (described in the statistical analysis
section) of the LCQ and the SGRQ. Only the correlation
between the psychological domain of the LCQ and the
corresponding impact domain of the SGRQ was low to
moderate and did not meet the pre-defined minimal
level of 0.50.
Correlation coefficients for the LCQ and most of the
corresponding domains of the SF-36 were low, and
almost non existent for the psychological domain.
Except the correlations between the social domain of
the LCQ and the social functioning domain of the SF-36
(r = 0.41; p = 0.002).
Table 1 Patient characteristics
n5 4
Sex, male, n (%) 40 (74)
Age (years), mean (SD) 68 ± 10
Pack-years, mean (SD) 36 ± 22
Current smoker, n (%) 22 (41)
FEV1 (litres)* 1.3 ± 0.5
FEV1 % predicted 47 ± 13
COPD GOLD, n (%)† II 27 (50)
III 19 (35)
IV 8 (15)
Respiratory medication, n (%) Inhaled corticosteroids 51 (94)
Short acting bronchodilator‡ 2 (4)
Long acting bronchodilator§ 35 (65)
Both ║ 17 (31)
* Forced Expiratory Volume in one second
† Classification by the global initiative for Chronic Obstructive Lung Disease
[3]
‡ Short acting bronchodilator: short acting beta-2 agonist and/or short acting
anticholinergic
§ Long acting bronchodilator: long acting beta-2 agonist and/or long acting
anticholinergic
║ Both long and short acting beta-2 agonist and/or anticholinergic
bronchodilators
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The internal consistency of the LCQ, shown in table 4
in the column on the right, was adequate (≥ 0.70) for
two of the three domains and the total questionnaire,
with Cronbach’s alpha coefficients ranging from 0.74 to
0.86. For the physical domain the Cronbach’sa l p h a
coefficient was 0.67. The results were comparable with
the studies by Birring and Huisman in the more general
population presenting with cough but not necessarily
with COPD (table 4) [16,17].
Reproducibility
Reproducibility was tested in 24 stable patients. The
ICC’sf o rt h eL C Qa r es h o w ni nt a b l e5 .E x c e p tf o rt h e
psychological domain all repeated measurements were
highly correlated, which indicates high test-retest relia-
bility. A Bland-Altman plot of the LCQ total score is
shown in Figure 1. The mean difference after two weeks
was 0.73 (± 1.75). The upper limit of agreement for the
LCQ total score is 4.16 and the lower limit of agreement
-2.70.
Responsiveness
Eleven of the forty-nine patients perceived a significant
improvement in cough (GRC≥4). In these patients the
mean change in the total LCQ score after 12 weeks was
4.3 ± 2.5. The Area Under the Curve (AUC) of the ROC
was 0.85 (95%CI 0.73; 0.97, p < 0.001, n = 49), Figure 2.
Table 2 Baseline health status scores
mean (SD) Range
LCQ* physical 4.2 (± 0.8) (1.8 - 5.8)
psychological 4.8 (± 1.0) (2.3 - 6.6)
social 4.6 (± 1.3) (1.0 - 6.5)
total 13.6 (± 2.8) (5.9 - 18.1)
SGRQ† symptoms 65.3 (± 17.4) (26.7 - 92.8)
activity 66.2 (± 24.3) (0 - 100)
impact 39.9 (± 18.9) (1.6 - 77.3)
total 52.1 (± 18.5) (5.9 - 81.2)
SF-36‡ physical functioning 36.1 (± 25.2) (0 - 90)
role physical 23.1 (± 35.6) (0 - 100)
pain 61.6 (± 25.6) (22 - 100)
general health 32.6 (± 19.0) (0 - 75)
vitality 47.1 (± 18.3) (15 - 90)
social functioning 65.0 (± 27.1) (0 - 100)
role emotional 72.0 (± 37.5) (0 - 100)
mental health 69.6 (± 18.7) (24 - 100)
* Leicester Cough Questionnaire
† St. George’s Respiratory Questionnaire, a disease-specific health status
questionnaire
‡ Short form 36, a generic health status questionnaire
Table 3 Concurrent validity
LCQ*
Physical Psychological Social Total
SGRQ†
Symptoms -0.57 (54; < 0.001) -0.45 (54; 0.001) -0.51 (53; < 0.001) -0.58 (53; < 0.001)
Activity -0.58 (54; < 0.001) -0.11 (54; 0.42) -0.39 (53; 0.004) -0.42 (53; 0.002)
Impact -0.67 (54; < 0.001) -0.31 (54; 0.023) -0.60 (53; < 0.001) -0.61 (53; < 0.001)
Total -0.68 (54; < 0.001) -0.28 (54; 0.037) -0.57 (53; < 0.001) -0.60 (53; < 0.001)
SF-36‡
Physical functioning 0.39 (54; 0.004) 0.06 (54; 0.65) 0.29 (53; 0.039) 0.28 (53; 0.041)
Role physical 0.31 (53; 0.022) 0.05 (53; 0.72) 0.23 (52; 0.099) 0.22 (52; 0.11)
Pain 0.47 (53; < 0.001) 0.29 (53; 0.038) 0.47 (52; 0.001) 0.47 (52; < 0.001)
General health 0.42 (54; 0.002) 0.25 (54; 0.072) 0.36 (53; 0.008) 0.37 (53; 0.007)
Vitality 0.64 (54; < 0.001) 0.24 (54; 0.086) 0.49 (53; < 0.001) 0.50 (53; < 0.001)
Social functioning 0.41 (54; 0.002) 0.32 (54; 0.017) 0.41 (53; 0.002) 0.43 (53; 0.001)
Role emotional 0.05 (53; 0.70) 0.04 (53; 0.77) 0.13 (52; 0.38) 0.10 (52; 0.48)
Mental health 0.40 (54; 0.003) 0.30 (54; 0.026) 0.37 (53; 0.006) 0.44 (53; 0.001)
Spearman correlation coefficients are presented (n; p-value).
* Leicester Cough Questionnaire
† St. George’s Respiratory Questionnaire, a disease-specific health status questionnaire
‡ Short form 36, a generic health status questionnaire
Table 4 Internal consistency
Cronbach’s alpha coefficient
LCQ* Birring[16]† Huisman[17]† This study‡
physical 0.79 0.77 0.67
psychological 0.89 0.84 0.75
social 0.85 0.83 0.74
total 0.92 0.93 0.86
* Leicester Cough questionnaire
† patients with chronic cough
‡ patients with COPD and chronic productive cough
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ered to be adequate [27]. Thus, the LCQ was able to
detect changes in this specific group of patients.
Floor or ceiling effect
Floor or ceiling effects (the worst or the best possible
score) were analysed at baseline, table 2. Only one
patient (1.9%) had the worst possible score in the social
domain of the LCQ. No best possible scores were
found. Thus, floor or ceiling effects were not present,
both in the domains and in the total questionnaire.
Discussion
This study is the first to examine the validity and preci-
sion of the LCQ specifically in COPD patients with
chronic productive cough. It shows that the LCQ in
these patients reliably measures the same construct as
the original LCQ in patients with chronic cough in the
general population. Responsiveness analysis indicated
that the change in LCQ total scores after 12 weeks was
able to predict which patients reported improved health
status and which did not. No floor or ceiling effects
were present which assured good content validity.
Good concurrent validity of the LCQ was found in
relation to the SGRQ but not with the SF-36. This may
be explained by both questionnaires measuring different
concepts, but more importantly, this is caused by the
nature of these questionnaires: the LCQ measures symp-
tom-specific health status and the SGRQ COPD-specific
health status, while the SF-36 measures generic health
status. The results regarding concurrent validity were in
accordance with Birring’s original validation study but
slightly lower compared to the Dutch validation of the
LCQ [16].
Table 5 Reliability
Intraclass correlation coefficient 95%CI*
LCQ† Birring
[16]‡
Huisman
[17]‡
This
study§
Physical 0.93 0.86 0.93 0.84;
0.97
Psychological 0.90 0.93 0.79 0.51;
0.91
Social 0.88 0.93 0.88 0.72;
0.95
Total 0.96 0.93 0.92 0.81;
0.96
* 95% Confidence Interval for ICC this study
† Leicester Cough Questionnaire
‡ patients with chronic cough
§ patients with COPD and chronic productive cough
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Figure 1 Bland-Altman plot of LCQ total score repeated over 2 weeks in stable patients representing agreement. The mean difference
over 2 weeks is represented by the solid line. The dashed lines are the limits of agreement, which represent 2 times the standard deviation of
the mean difference.
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tency, supporting the hypothesis that the associated
questionnaire items are related to each other but do not
completely overlap in which case the Cronbach’sa l p h a
would have a value of 1, and the item (or domain)
would be redundant. The exception with poorer internal
consistency was the physical domain (Cronbach’sa l p h a
coefficient = 0.67). Three items contributed most to the
lower Cronbach’s alpha in the physical domain: loss of
energy, hoarseness and smoking (questions 9, 14 and
15). As most patients with COPD have a smoking his-
tory and many suffer form loss of energy or hoarseness
these three items may be less discriminative in COPD
patients than in patients with chronic cough. When
these items were removed from this domain, the Cron-
bach’s alpha coefficient increased to almost 0.70.
Previous studies showed comparable Cronbach’sa l p h a
coefficients which varied between 0.77 and 0.91, except
for the physical domain [16,17].
To examine reproducibility, test-retest reliability and
agreement were assessed after two weeks in clinically
stable patients. Total score and scores on all domains
were repeatable with intraclass correlation coefficients
above 0.7. So, repeatability of the LCQ in COPD
patients with chronic cough was adequate and in accor-
dance with previous results [16,17].
Agreement was assessed in clinically stable patients
after 2 weeks according to the method described by
Bland and Altman [29]. We found a mean change in the
LCQ total score of 0.73 (± 1.75), similar to the results of
Birring (0.73 (± 0.94)) after two weeks [16]. Agreement
is regarded as acceptable when the limits of agreement
are smaller than the minimal clinical important differ-
ence (MCID). In previous studies the MCID for the
LCQ total score in patients with chronic cough was esti-
mated between 1.3 (± 2.3) and 2.8 (± 2.0) [31,32]., In
this study we found limits of agreement above these
values, indicating inadequate agreement. However, we
realise that this randomised controlled trial was not the
ideal setting to measure reproducibility specifically since
patients received either active (azithromycin) or placebo
medication from the first day. This treatment/placebo
difference will have increased noise, resulting in larger
limits of agreement and rendering assessment of repro-
ducibility poorer. To draw a more definitive conclusion
this analysis should therefore be repeated in clinically
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Figure 2 Receiver Operating Curve for responsiveness of the LCQ total score in COPD patients with chronic cough (n = 49). The Area
Under the Curve is 0.85 (95%CI: 0.73; 0.97).
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medication. The MCID specifically for COPD patients
with chronic cough should also be obtained.
The LCQ has been validated and used primarily in
patients suffering from chronic cough but not exclu-
sively. Murray et al validated the LCQ in patients with
bronchiectasis. They concluded that the questionnaire
was able to measure quality of life for assessing existing
and new therapies [19]. Both concurrent validity, relia-
bility and responsiveness were comparable with our
results. Polley et al undertook a cross-sectional compari-
son of the LCQ and the Cough specific Quality of life
Questionnaire (CQLQ) in patients with either chronic
cough, bronchiectasis, COPD or asthma. The group of
COPD patients was small (n = 18), but had similar base-
line LCQ scores as our participants. They demonstrated
significant concurrent validity (r = -0.49) for the total
score of the LCQ and the CQLQ in COPD patients.
Remarkably, we found a better concurrent validity (r =
-0.60) when using the SGRQ, which is not a cough-spe-
cific questionnaire. Like in our study, the psychological
domain in their study showed weaker correlations in
COPD patients than in patients with chronic cough.
They reasoned that chronic cough is associated with
more psychological problems in women than in men. In
both studies the majority of patients included were
male, in Polley et al 83% and in our study 74%. Possibly
the relatively weak correlations can be explained by this
gender imbalance. An additional explanation, they sug-
g e s t ,i st h a ti nC O P Dp a t i e n t sp h y s i c a lc o m p l a i n t sa r e
more prevalent than in chronic cough patients, in which
psychosocial complaints are predominant [33].
There are some limitations to our study. First it is
based on participants in the setting of a randomised
double-blind controlled trial. During the analyses of this
validity study it was unknown which participants were
treated with antibiotics and which were not. In case of
significant treatment effect, this will, as earlier men-
tioned, have influenced reproducibility. Secondly, to
assess internal consistency Cronbach’s alpha coefficients
as well as factor analysis is recommended. The latter
analysis was not done in our study, because another
method of item reduction was used during the develop-
ment of the LCQ [16]. Furthermore, we realise that it is
difficult to confirm factor structures in different popula-
tions [34]. And last, the SGRQ was used as the reference
standard. A recent study showed that the SGRQ mea-
sures health status only partly. It concluded that the
SGRQ can be used mainly for measuring subjective
symptoms and impairments and that other aspects of
health status such as physical activity, dyspnoea, fatigue
or quality of life in general are covered less. Preferably,
different questionnaires should be combined [35].
Ideally, questionnaires which measure health status
should be both discriminative (able to distinguish
patients with different degrees of disease severity) and
evaluative (able to detect within patients changes follow-
ing therapy). In this study the emphasis is mostly on the
evaluative properties of the LCQ, because the main goal
of the study was to validate the LCQ for use in clinical
trials. The discriminative properties should be assessed
in a future study.
In summary, our study shows that the LCQ can be
used in COPD patients to measure cough-related health
status. This provides a tool to study the antitussive or
mucolytic effects of drugs in patients with COPD and
chronic productive cough.
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